Consistent with this, treatment with an HSP90 inhibitor was shown to degrade and deplete expression of BRCA1, ATR and CHK1, resulting in impairment of the DDR and DNA repair, which sensitized breast cancer cells to DNA damage [6, 7]. This evidence concerns the gene HSP90AA1 and breast carcinoma.